JP2018508491A5 - - Google Patents

Download PDF

Info

Publication number
JP2018508491A5
JP2018508491A5 JP2017540129A JP2017540129A JP2018508491A5 JP 2018508491 A5 JP2018508491 A5 JP 2018508491A5 JP 2017540129 A JP2017540129 A JP 2017540129A JP 2017540129 A JP2017540129 A JP 2017540129A JP 2018508491 A5 JP2018508491 A5 JP 2018508491A5
Authority
JP
Japan
Prior art keywords
oeg
γglu
pharmaceutical composition
human insulin
desb30 human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017540129A
Other languages
English (en)
Japanese (ja)
Other versions
JP6737793B2 (ja
JP2018508491A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/051813 external-priority patent/WO2016119854A1/en
Publication of JP2018508491A publication Critical patent/JP2018508491A/ja
Publication of JP2018508491A5 publication Critical patent/JP2018508491A5/ja
Application granted granted Critical
Publication of JP6737793B2 publication Critical patent/JP6737793B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017540129A 2015-01-29 2015-01-29 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物 Expired - Fee Related JP6737793B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2015/051813 WO2016119854A1 (en) 2015-01-29 2015-01-29 Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020082000A Division JP2020117542A (ja) 2020-05-07 2020-05-07 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物

Publications (3)

Publication Number Publication Date
JP2018508491A JP2018508491A (ja) 2018-03-29
JP2018508491A5 true JP2018508491A5 (es) 2019-10-03
JP6737793B2 JP6737793B2 (ja) 2020-08-12

Family

ID=52462305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017540129A Expired - Fee Related JP6737793B2 (ja) 2015-01-29 2015-01-29 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物

Country Status (5)

Country Link
US (1) US20180000742A1 (es)
EP (1) EP3250225A1 (es)
JP (1) JP6737793B2 (es)
CN (1) CN107206059A (es)
WO (1) WO2016119854A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3668892A1 (en) 2017-08-17 2020-06-24 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof
EP3894391A1 (en) 2018-12-11 2021-10-20 Sanofi Peptide binder
WO2021029467A1 (en) * 2019-08-14 2021-02-18 Sam Chun Dang Pharm. Co., Ltd. A solid dosage form for orally administration
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2023166179A1 (en) 2022-03-03 2023-09-07 Cyprumed Gmbh Improved oral pharmaceutical formulations of therapeutic peptides and proteins
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935326A (en) * 1967-06-28 1976-01-27 Boehringer Mannheim G.M.B.H. Process for coating tablets with aqueous resin dispersions
GB9414045D0 (en) * 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
CN1863510A (zh) * 2003-08-13 2006-11-15 比奥孔有限公司 用于治疗剂的微-粒子脂肪酸盐固体剂量制剂
RU2428178C2 (ru) * 2004-06-07 2011-09-10 Вайет Сахарные покрытия и способы их применения
US7605123B2 (en) * 2004-07-19 2009-10-20 Biocon Ltd. Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
KR101729986B1 (ko) * 2006-09-22 2017-04-25 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
JP5868594B2 (ja) * 2007-10-16 2016-02-24 バイオコン・リミテッドBiocon Limited 経口投与可能な固形医薬組成物及びそのプロセス
DK2910570T3 (en) * 2008-03-18 2017-01-30 Novo Nordisk As Protease-stabilized acylated insulin analogues.
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
WO2011084618A2 (en) * 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CN102335431B (zh) * 2010-07-14 2015-08-26 上海蓝心医药科技有限公司 一种给药组合物及其制备和使用方法
CN102985440B (zh) * 2010-06-23 2016-10-26 诺沃-诺迪斯克有限公司 包含额外的二硫键的胰岛素衍生物
JP2015502971A (ja) * 2011-12-21 2015-01-29 ノヴォ ノルディスク アー/エス N末端修飾インスリン誘導体
EP3003267A1 (en) * 2013-05-30 2016-04-13 Novo Nordisk A/S Novel oral pharmaceutical composition for treatment of diabetes

Similar Documents

Publication Publication Date Title
JP2018508491A5 (es)
HRP20200753T1 (hr) Farmaceutske formulacije koje sadrže dapagliflozin propilen glikol hidrat
RU2016151697A (ru) Расправляемая удерживаемая в желудке лекарственная форма
JP2008501025A5 (es)
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
HRP20231613T1 (hr) Pripravci koji sadrže sredstvo za unošenje i njihova priprava
SI2760821T1 (en) A salt salt of an anti-inflammatory substituted cyclobutenedione compound
JP2013100317A5 (es)
JP2015515459A5 (es)
JP2011079859A5 (es)
JP2015510916A5 (es)
JP2015038135A5 (es)
IL195732A (en) Pharmaceutical compounds containing passoterodine, their use and method for their preparation
JP2018184458A5 (es)
JP2019516739A5 (es)
AR094374A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos
JP2013522326A5 (es)
JP2016510326A5 (es)
ES2957495T3 (es) Formulaciones de comprimidos de liberación modificada que contienen inhibidores de fosfodiesterasa
PE20130657A1 (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
WO2020138791A3 (ko) 토파시티닙 또는 그의 약제학적으로 허용되는 염을 함유한 서방성 제제 및 그의 제조방법
AR100977A1 (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
KR102055859B1 (ko) 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합
EP3513811A1 (en) Delayed release dosage forms comprising dimethyl fumarate
RU2018137590A (ru) Фармацевтические композиции для производного n-пропаргиламина